| Primary |
| Anaesthesia |
18.8% |
| General Anaesthesia |
15.0% |
| Prophylaxis |
12.5% |
| Induction Of Anaesthesia |
8.1% |
| Product Used For Unknown Indication |
6.9% |
| Tooth Extraction |
6.3% |
| Drug Abuse |
5.6% |
| Sedation |
5.0% |
| Complex Regional Pain Syndrome |
4.4% |
| Pain |
2.5% |
| Epilepsy |
1.9% |
| Maintenance Of Anaesthesia |
1.9% |
| Sedative Therapy |
1.9% |
| Substance Use |
1.9% |
| Analgesic Therapy |
1.3% |
| Arthralgia |
1.3% |
| Depression |
1.3% |
| Drug Resistance |
1.3% |
| Drug Use For Unknown Indication |
1.3% |
| Endotracheal Intubation |
1.3% |
|
| Hypotension |
19.7% |
| Toxicity To Various Agents |
8.2% |
| Apnoea |
6.6% |
| Drug Abuse |
6.6% |
| Bradycardia |
4.9% |
| Face Oedema |
4.9% |
| Medication Error |
4.9% |
| Unresponsive To Stimuli |
4.9% |
| Cholestasis |
3.3% |
| Convulsion |
3.3% |
| Corneal Oedema |
3.3% |
| Cystitis |
3.3% |
| Death |
3.3% |
| Hepatic Function Abnormal |
3.3% |
| Hypertension |
3.3% |
| Life Support |
3.3% |
| Overdose |
3.3% |
| Pulseless Electrical Activity |
3.3% |
| Suicidal Ideation |
3.3% |
| Suprapubic Pain |
3.3% |
|
| Secondary |
| Product Used For Unknown Indication |
19.2% |
| Drug Use For Unknown Indication |
16.6% |
| Pain |
11.6% |
| Anaesthesia |
10.1% |
| Induction Of Anaesthesia |
8.1% |
| General Anaesthesia |
5.5% |
| Analgesic Therapy |
4.3% |
| Sedation |
3.9% |
| Maintenance Of Anaesthesia |
2.5% |
| Cancer Pain |
2.2% |
| Electrolyte Substitution Therapy |
2.2% |
| Arthritis |
1.8% |
| Stupor |
1.8% |
| Hypertension |
1.7% |
| Hypotonia |
1.7% |
| Thrombosis Prophylaxis |
1.5% |
| Prophylaxis |
1.4% |
| Restlessness |
1.3% |
| Premedication |
1.2% |
| Procedural Pain |
1.2% |
|
| Renal Failure Acute |
16.4% |
| Transaminases Increased |
12.3% |
| Anaphylactic Shock |
8.2% |
| Drug Abuse |
5.8% |
| Somnolence |
5.3% |
| Drug Ineffective |
4.7% |
| Bradycardia |
4.1% |
| Cardiac Arrest |
4.1% |
| Stevens-johnson Syndrome |
4.1% |
| Drug Interaction |
3.5% |
| Posterior Reversible Encephalopathy Syndrome |
3.5% |
| Respiratory Arrest |
3.5% |
| Respiratory Depression |
3.5% |
| Vomiting |
3.5% |
| Acute Hepatic Failure |
2.9% |
| Death |
2.9% |
| Hyperaesthesia |
2.9% |
| Sedation |
2.9% |
| Toxic Epidermal Necrolysis |
2.9% |
| Toxicity To Various Agents |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
34.9% |
| Drug Use For Unknown Indication |
20.7% |
| Pain |
10.0% |
| Sedation |
6.1% |
| Anaesthesia |
3.6% |
| Prophylaxis |
3.0% |
| Nausea |
2.6% |
| Induction Of Anaesthesia |
2.3% |
| General Anaesthesia |
1.7% |
| Acute Lymphocytic Leukaemia |
1.6% |
| Convulsion |
1.6% |
| Cardiopulmonary Bypass |
1.5% |
| Hypertension |
1.5% |
| Coronary Artery Bypass |
1.3% |
| Maintenance Of Anaesthesia |
1.3% |
| Analgesic Therapy |
1.3% |
| Cancer Pain |
1.3% |
| Non-hodgkin's Lymphoma |
1.2% |
| Asthma |
1.2% |
| Breast Cancer |
1.2% |
|
| Strabismus |
7.6% |
| Vomiting |
7.6% |
| Tachycardia |
6.8% |
| Aspartate Aminotransferase Increased |
5.9% |
| Pain |
5.9% |
| Renal Failure |
5.9% |
| Ventricular Tachycardia |
5.9% |
| Rash |
5.1% |
| Somnolence |
5.1% |
| Visual Acuity Reduced |
5.1% |
| Fear |
4.2% |
| Hypotension |
4.2% |
| Injury |
4.2% |
| Nausea |
4.2% |
| Pneumonia |
4.2% |
| Rhabdomyolysis |
4.2% |
| Bronchospasm |
3.4% |
| Disseminated Intravascular Coagulation |
3.4% |
| Hyperbilirubinaemia |
3.4% |
| Oophorectomy |
3.4% |
|
| Interacting |
| Cancer Pain |
32.6% |
| Product Used For Unknown Indication |
20.9% |
| General Anaesthesia |
9.3% |
| Pain |
9.3% |
| Renal Cancer Metastatic |
9.3% |
| Anaesthesia |
7.0% |
| Abdominal Pain Upper |
2.3% |
| Complex Regional Pain Syndrome |
2.3% |
| Induction Of Anaesthesia |
2.3% |
| Intraoperative Care |
2.3% |
| Premedication |
2.3% |
|
| Depressed Level Of Consciousness |
20.0% |
| Drug Interaction |
13.3% |
| General Physical Health Deterioration |
13.3% |
| Somnolence |
13.3% |
| Agitation |
6.7% |
| Areflexia |
6.7% |
| Hepatic Function Abnormal |
6.7% |
| Motor Dysfunction |
6.7% |
| Performance Status Decreased |
6.7% |
| Toxicity To Various Agents |
6.7% |
|
